HSD11B2

Across TCGA pan-cancer cohorts, HSD11B2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of HSD11B2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where HSD11B2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types HSD11B2 is over-expressed in tumor, although a few such as CCRCC and COAD show the opposite, repressed pattern.

CCRCC, COAD, and LSCC are the cancer types where HSD11B2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in HSD11B2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	IV	−1.924	<.001	12	view →
COAD	Female	III,IV	−1.620	<.001	12	view →
LSCC	Male	II,III,IV	−0.754	<.001	8	view →
PDAC	Female	II,III,IV	−0.333	.048	2	view →
LUAD	Female	III,IV	+0.733	.049	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

HSD11B2–CCRCC

Open the CCRCC breakdown →